(0.10%) 5 251.75 points
(0.05%) 39 662 points
(0.21%) 18 293 points
(0.29%) $78.49
(1.60%) $2.29
(-1.19%) $2 346.70
(-0.53%) $28.36
(0.07%) $1 007.90
(-0.10%) $0.927
(0.19%) $10.85
(-0.02%) $0.798
(-1.27%) $91.49
Live Chart Being Loaded With Signals
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada...
Stats | |
---|---|
Today's Volume | 4 424.00 |
Average Volume | 16 219.00 |
Market Cap | 35.84M |
EPS | $0 ( 2024-04-03 ) |
Next earnings date | ( $0 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.770 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-02 | Warma Neil K | Buy | 200 000 | Option (right to buy) |
2023-12-04 | Sclar Jeremy M. | Buy | 150 000 | Series 2 Preferred Shares, no par value |
2022-10-11 | Sclar Jeremy M. | Buy | 26 217 | Warrants to Purchase Common Shares, no par value |
2023-12-04 | Sclar Jeremy M. | Sell | 150 000 | Series 1 Preferred Shares, no par value |
2023-12-25 | Title 19 Promis | Sell | 0 | Common Shares, no par value |
INSIDER POWER |
---|
-43.19 |
Last 83 transactions |
Buy: 847 135 | Sell: 2 093 488 |
ProMIS Neurosciences, Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
ProMIS Neurosciences, Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-1.070 |
FY | 2023 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-1.070 |
FY | 2022 |
Revenue: | $0 |
Gross Profit: | $0 (0.00 %) |
EPS: | $-1.700 |
Financial Reports:
No articles found.
ProMIS Neurosciences,
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators